For relevant Imatinib therapy against Philadelphia (Ph)-positive leukemias, it is essential to monitor mutations in the chimerical bcr-abl tyrosine kinase domain (TKD). However, there is no universally acceptable consensus on how to efficiently identify mutations in the target TKD. Recently, high-resolution melting (HRM) technology was developed, which allows gene scanning using an inexpensive generic heteroduplex-detecting dsDNA binding dye. This study aimed to validate HRM's introduction in a practical clinical setting for screening of mutations in sporadic sites of the chimerical bcr-abl TDK. All chimerical and wild-type abl TKD regions selectively amplified were used for HRM assays and direct sequencing. The HRM test had approximately 2.5 to 5% detection sensitivity for mutations. In contrast to mixture samples with mutant and wild-type cells, all mutant cell samples had indeterminate melting curves equivalent to those of the wild-type due to formation of only a homodulex. This issue was improved by the addition of exogenous wild-type DNA after PCR.
Introduction
The small chemical agent of Imatinib has a high therapeutic response rate for diseases carrying the chimerical bcr-abl gene. For example, the first Imatinib treatment was reported to give approximately 80% and 60% complete molecular response rates in chronic myelogeneuos leukemia (CML) and Philadelphia (Ph)-positive acute lymphoblastic leukemia (ALL), respectively 1, 2) . However, in many cases mutations in the chimerical abl Tyrosine kinase domain (TKD) were revealed to precede resistance to Imatinib, resulting in disease relapse and progression to advanced disease. At present, although it is known that there are several causative factors in resistance, such as expression of a rapid drug efflux protein and non bcr-abl-dependent transformation involving the src family, TDK mutations in the chimerical gene are thought to play a major role in resistance acquisition 3) . Therefore, detection of mutations becomes essential in cases treated with Imatinib. Moreover, mutations associated with Imatinib therapy emerge as a Ph-positive subclone from minimal residual leukemia（MRD）even in the hematological remission period 4, 5) . This indicates the need for highly sensitive tests to detect only Ph-positive leukemic clones. To date, several methods to analyze mutations including direct and subcloning sequencing have been employed, but respective methods have merits and demerits, and are not always sensitive 6) . Recently, to analyze genetic variations (SNPs, Mutations, and methylations), a novel melting analysis called high-resolution melting (HRM) with an automated instrument and real-time PCR apparatus has been used 7, 8) . HRM is used to characterize samples according to their dissociation profile as they transit from double-strand DNA (dsDNA) to single-strand (ssDNA). Therefore, mixture samples with mutant and wild-type cells are easily identified by differences in melting curve shapes. mutant sequence variants produce a Tm shift compared with the wild-type 9) . In addition, it is a reliable-and closed-tube system without high-cost fluorescence probes 10, 11) . Thus, to introduce HRM assays in clinical settings to detect Ph-positive subclones with bcr-abl kinase domain mutations, the relevance and validation of the assay prior to direct sequencing was studied.
Materials and Methods

Samples and processing of cDNA
A total of 19 Ph-positive samples were used, consisting of 10 unlinked and already mutation-known specimens, 8 fresh practical samples from 6 patients with CML, 2 patients with ALL and one sample from a Ph-positive K562 cell line.
All patients with Ph-positive leukemias were being treated with Imatinib at 400-800mg per day and had hematological remission, but were positive for bcr-abl real-time RT PCR. As controls, 16 peripheral blood samples from normal volunteers and 10 cell lines consisting of HTLV-1-associated cell lines (Hut102, KK1, KOB, OMT, MT2, SO4, ST1), T-cell lines of Jurkat and MOLT4, and the monocytic line U937 were used.
The total RNA was extracted from total leukocyte guanidinium thiocyate lyates using an RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA was synthesized using oligo-dT primers and Superscript III reverse transcriptase (Invtrogene, Carsland, CA, USA). Practical and stocked samples used in this study were applied under the approval (15040708) of the Ethics Committee and the condition of the criteria of the Japanese Association of Laboratory Medicine.
Study Design for HRM assay in the chimerical abl-TDK region:
Our study for detection of mutation was designed as the two step manner: firstly, genetic alteration screening by HRM analysis (Figure 1 ), using the LightCycler 480 (Roche Molecular System, Alameda, CA, USA) for HRM and real-time thermal cycling, secondly, only samples positively screened by HRM were directly sequenced. First of all, each sample was examined for bcr-abl chimerical status by the conventional method 12) . If positive for Major or minor chimerical types, these bcr-abl kinase domains were selectively amplified, generating a fragment of 1504 bp for b2/a2 and 1579 bp for b3/a2, using primers previously reported 13) .
For HRM analysis, PCR products of 50-250bp length are recommended for best discrimination. Therefore, we applied a modified method previously reported by Polakova et al 10) , 10) , and 1M GC Melt, according to the instructions of Roche Applied Science (Manheim, Germany). The PCR was monitored by real-time cycling and a strong fluorescent signal was generated only when bound to dsDNA, that is the touch down PCR cycling and HRM conditions 17) . HRM melting curve data were obtained by slowly increasing the 6 temperature, from 60 to 90℃ at a rate of 100 acquisitions per 1℃. The melting status and changes in Tm value were analyzed using the Roche HRM algorithm (Gene Scanning Software, Roche Supplied Science, Manheim, Germany), depicting graphs of fluorescence-normalized and temperature-shifted melting curves and difference plots. The cell line K562 was used as a wild-type reference sample.
Sequencing:
In this study, to compare to accuracy of HRM analysis, regardless of the first step negative samples, all of the samples used were confirmed by sequencing the regions of the selectively amplified chimerical abl TKD, as well as abl TKD from Ph-negative controls using a Big Dye terminator kit Ver 3.1 (Applied Biosystems, Carsland, CA, USA) and the ABl Prism 3130 Genetic Analyzer (Applied Biosystems) according to the manufacturer's instructions.
Results
HRM assay validation:
For HRM scoring, Ph(+) K562 was set up as a wild-type genotype and the 2 or 3 normal blood samples were monitored as negative controls. First of all, using three different samples with mutations, HRM analysis in duplicate was performed, generating constant positive melting curves both in terms of shape and peak height with a range of melting temperatures (Tm) from 84-86℃ (Fig 2) .
On the other hand, 16 samples without the Ph-chromosome constantly produced the wild-type scanning profiles according to the Roche HRM program, as shown 
HRM assay results
The HRM assay was blindly examined in duplicate by a single researcher and then compared to sequencing data. As summarized in Table 1 , the HRM test . A novel technology of HRM with development of instruments and saturating intercalating dyes is emerging for detection of nucleic acid sequence variations and is now applyed in practical diagnostic settings 15, 16) . the two step method allows to avoid the direct sequencing for the entire region of all samples.
In this study, the HRM in our system was shown to efficiently and simply differentiate mutations in the chimerical bcr-abl TDK region by using LightCycler technology and a software algorithm. In particular, it is noteworthy that mixture samples with mutant and wild-type cells was easily and high sensitively (approximately 5%) detectable. On the other hand, samples with all mutant cells often presents with indeterminate low peaks in difference plots, causing confusing interpretations. This is probably the main defect in this HRM technology resulting from a dependency on heteroduplex formation due to the mixture ratio of the mutant and wild-type. Therefore, to avoid false-negatives with samples containing all mutant cells, it was shown that the addition of exogenous control DNA was useful (Fig 4 and 5) . Actually, since the ratio of mutant cells in the samples is unknown in practical samples, we adopted an HRM assay system which measures using a double feature; an original one and mixtures of the mutant and exogenous wild-type DNA with the ratio of 1:1.
Practical examples are shown in Fig 5, indicating that the mixed sample (left panel) makes it easy to discriminate, whereas the change in the positive peak pattern was tolerable if a 40%mutant sample was diluted up-to 50%.
Finally, our HRM results were accordant in all but one out of 45 samples with an accordance rate of 98.7% compared with sequencing data. The discrepancy in the results in one sample was expected due to an accidental relation between the primer and mutation sites, as described above. The quality of HRM is thought to be highly dependent on real-time amplification, so that we are now revising part of the primer set and appropriate sequence length for HRM.
Clearly, this is a rapid, simple, accurate screening method using HRM technology for chimerical bcr-abl TDK mutations involved in resistance to 
